Pulmonary arterial hypertension (PAH) is a serious and uncommon condition that poses a threat to one’s life. The function of the pulmonary arteries is to transport blood from the heart to the lungs, where it undergoes oxygenation before being distributed throughout the body. However, in individuals with PAH, these small arteries become constricted and narrower than usual. While diagnosing PAH is relatively straightforward, determining its underlying causes can be a complex task. Unfortunately, there is currently no cure for PAH, and managing the condition can be challenging. Therefore, treatment focuses on slowing down the progression of the disease.
Understanding Gene Mutation and its Association with Pulmonary Arterial Hypertension
Pulmonary arterial hypertension, categorized in Group 1 of pulmonary hypertension, can be caused by a specific gene mutation found in certain families. This mutation is known as heritable pulmonary arterial hypertension (HPAH) and is a progressive and potentially life-threatening condition. The presence of this mutation in predisposed genes leads to elevated pulmonary arterial resistance, preventing the smooth flow of blood through the circulatory system. Consequently, this lack of blood flow results in the failure of the right side of the heart chambers.
Certain drugs
Prolonged usage of certain drugs like cocaine and amphetamines has been linked to the development of pulmonary arterial hypertension (PAH). Although specific weight loss medications that were commonly used in the 1990s are no longer used in the medical weight loss profession, they were also known to contribute to the onset of PAH. Furthermore, over-the-counter pain medications called NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen, naproxen, and celecoxib can potentially worsen symptoms of pulmonary arterial hypertension if used excessively. These medications can exert pressure on the kidneys, promote fluid retention, and exacerbate any pre-existing kidney conditions.